17 results about "MTORC1" patented technology

The invention provides application of a small molecule drug for promoting triple negative breast cancer ferroptosis, and belongs to the technical field of tumor treatment. The inducer can effectively kill triple negative breast cancer cells by triggering a ferroptosis pathway. The invention discovers that the inhibitor can reduce the expression of a key protein RPTOR by inhibiting the activity of an mTORCl compound, thereby weakening the anti-oxidation defense capability of triple negative breast cancer cells, greatly enhancing the accumulation of lipid peroxide, and further strongly inducing the occurrence of ferroptosis. The component of the culture medium is a DMEM (Dulbecco Modified Eagle Medium) containing 10% of fetal calf serum, and 2 [mu] M of Torinl is added at the same time. The invention discloses a new target spot of ferroptosis of the triple-negative breast cancer, and provides a new thought for treatment of the triple-negative breast cancer.

The invention belongs to the technical field of biological medicines, and particularly relates to an mTORC1 selective degradation agent containing a hydrophobic label as well as a synthesis method and application of the mTORC1 selective degradation agent. The structural formula of the degradation agent is as shown in formula I. Representative compounds have the effect of inhibiting proliferation of various tumor cells, and can provide new research and development thoughts and directions for anti-tumor drugs. .

The present invention relates to compounds and methods useful for selectively modulating mTORC1 activity.The present invention describes compounds comprising a lithium salt and an mTORC1 activator in stoichiometric ratio or co-crystal form.Such mTORC1 activator can be an amino acid as described in published PCT application WO2017 / 070518.In some embodiments, the compounds comprising a lithium salt and an mTORC1 activator have improved efficacy due to the synergistic effect of lithium and mTORC1 activator.

The disclosure provides methods for the acute treatment of depression and / or anxiety, for the enhancement of mTOR (e.g., mTORC1) signaling, and for the reduction of neuroinflammation, comprising administering to a patient in need thereof, a therapeutically effective amount of a 5-HT2A or 5-HT2A / D2 receptor ligand, e.g. lumateperone.

A carcinostatic agent, a carcinogenesis inhibitor and / or a life-prolonging agent each comprising a compound with mTORC1 inhibitory effect, said compound having partial structures (I), (II) and (III), or a pharmacologically acceptable salt thereof. (In the formulae: R1, R2, R3 and R4 are the same or different and represent an H, a lower alkyl, a lower haloalkyl, a lower alkoxy, a lower alkylamino, an OH, a protected OH, an amino, a protected amino, a carboxy, a protected carboxy or a halogen atom; R5 and R6 are the same or different and represent an H or a protecting group of an OH, or R5 and R6 form together a methylene or dimethylmethylene group; and A represents O or S.)

The application belongs to the technical field of biological medicine, and provides application of astragaloside IV in preparation of a medicine for treating advanced ovarian cancer. The application analyzes and studies a targeting effect of AS-IV on CD276, determines a molecular mode of covalent combination of AS-IV and CD276, identifies a molecular mechanism of combination of AS-IV and CD276 through an E3 ubiquitin ligase and activation of an mTORC1 pathway of NK cells, and determines application potential of AS-IV in enhancement of NK cell anti-tumor immunity in preparation of an OC immunotherapy medicine.

The present invention includes compositions and methods for treating or preventing certain dermal disorders including dermal atrophy, pseudoscars, actinic keratosis, seborrheic or actinic keratoses, lentigines, focal areas of dermal thickening, and coarse wrinkles. In certain embodiments, the compositions useful within the invention comprise a therapeutically effective amount of a mTORC1 inhibitor and a dermatologically acceptable carrier.

The invention belongs to the technical field of gene engineering, and particularly relates to a method for constructing a knock-down pig RagB gene cell strain. The invention aims to provide an experimental material for improving the utilization rate of amino acid by livestock and poultry. According to the technical scheme, the method for constructing the pig RagB gene knock-down cell strain comprises the following steps: designing shRNA (short hairpin Ribonucleic Acid) of a targeted RagB gene, constructing the shRNA on an expression vector, and transfecting IPEC-J2 cells; the nucleotide sequence of the shRNA is as shown in Seq ID (Identity) No. 6, Seq ID No. 7, Seq ID No. 9, Seq ID No. 10, Seq ID No. 12 or Seq ID No. 13. The invention successfully clones the porcine RagB gene and constructs the knock-down cell strain of the porcine RagB gene. The cell strain provides an experimental material for the subsequent research of the function of the RagB protein and the understanding of the effect of the RagB protein in mTORC1.

Methods for treating diseases or disorders associated with an increase in mTORC1 activity or inflammation, or elevated NT-proBNP, as well as methods of inducing autophagy in the treatment of diseases and disorders, with an ActRII ligand trap.

Provided are a new venom polypeptide-dendrimer complex, and a preparation method therefor and the use thereof. Specifically, provided is a scorpion venom polypeptide, wherein the amino acid sequence of the scorpion venom polypeptide is FLGGLLSSIF. A new scorpion venom polypeptide (designated as C9) is isolated and identified. Moreover, a new polypeptide-polyamidoamine dendrimer complex G5C9 (i.e., nanoparticles) having a glioblastoma (GBM)-targeting effect is constructed. Compared with polypeptide C9, G5C9 exhibits significantly improved cellular uptake efficiency. G5C9 can enter cells via endocytosis and targets lysosomes, and inhibits lysosomal function and mTORC1, thereby promoting nuclear translocation of TFEB and further inducing autophagic cell death. Therefore, G5C9 provides a new targeted anti-GBM approach both in vitro and in vivo.

The present disclosure relates to MTORC1 modulators and uses thereof. In particular, the present disclosure provides compounds and salts that exhibit high selectivity and inhibitory activity for mTORC1 and their use for the treatment of disease.

The present invention includes compositions and methods for treating or preventing certain dermal disorders including dermal atrophy, pseudoscars, actinic keratosis, seborrheic or actinic keratoses, lentigines, focal areas of dermal thickening, and coarse wrinkles. In certain embodiments, the compositions useful within the invention comprise a therapeutically effective amount of a mTORC1 inhibitor and a dermatologically acceptable carrier.

Provided in the present disclosure are an siRNA for inhibiting PTOR mRNA expression, and a pharmaceutical composition and conjugate containing the siRNA. The siRNA contains a sense strand and an antisense strand, and each nucleotide in the siRNA is independently a modified or unmodified nucleotide, wherein the sense strand contains nucleotide sequence I that is equal in length to a nucleotide sequence as shown in SEQ ID NO: 1 and differs therefrom by no more than three nucleotides; and the antisense strand contains nucleotide sequence II that is equal in length to a nucleotide sequence as shown in SEQ ID NO: 2 and differs therefrom by no more than three nucleotides. The siRNA, pharmaceutical composition and conjugate provided in the present disclosure can be used as mTORC1 inhibitors to effectively treat related diseases caused by mTORC1 activation, and as autophagy inducers to treat autophagy-associated diseases or symptoms.